

Crohn's disease

Appendix B

Clinical Guideline <...>

Declarations of interest

10 October 2012

*Commissioned by the National Institute for
Health and Clinical Excellence*

Published by the National Clinical Guideline Centre at
The Royal College of Physicians, 11 St Andrews Place, Regents Park, London, NW1 4BT

First published 10 October, 2012

© National Clinical Guideline Centre – October 2012

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

Contents

Declarations of interest	5
--------------------------------	---

Declarations of interest

GDG meeting	Declaration of Interests	Action taken
Adrian Thomas		
1st GDG meeting 8th Sept 10	<p>I received an honorarium for attending the paediatric advisory board to Ferring on 23/09/09. I am also receiving sponsorship from Mead Johnson Nutritionals, Braun Medical and Danone Baby Nutrition for attending the ESPEN Congress from 5-8/09/10.</p> <p>I am an investigator in a research study looking at the use of rabeprazole in the management of gastro-oesophageal reflux in infants. There may be some financial payment to the department in which I work. Rabeprazole is produced by Johnson & Johnson.</p> <p>Advisor to the BSPGHAN quality initiative in biological treatment usage for paediatric inflammatory bowel disease.</p> <p>I was a co-applicant for a recent successful CICRA research project grant application entitled "BSPGHAN quality initiative in biological treatment usage for paediatric inflammatory bowel disease". The main aim is to establish a register of biological treatment usage in paediatric IBD in the UK. All of the grant money is going to colleagues in Edinburgh who are running the study and my role is really as an advisor.</p>	None
11th GDG meeting 7th Sept 11	Personal pecuniary interest declared for honorarium from Reckitt Benckiser for speaking at the Manchester Reflux conference (21/05/2011).	None
13th GDG meeting 9th Nov 11	I have received a fee from Mead Johnson to help with my expenses to attend the European Society of Paediatric Gastroenterology meeting in Italy in May.	None
15th GDG meeting 25th Jan 11	Received a fee from Pfizer to cover expenses for ESPGHAN conference last year.	Declare and participate
Alan Lobo		
1st GDG meeting 8th Sept 10	<p>Proctor and Gamble Pharmaceuticals – Payment for work in establishing Yorkshire and Humber IBD network; 24.7.09; No work specific to this or any company's product.</p> <p>Application made to P and G Pharmaceuticals (now Warner Chilcott) for funding of laboratory consumables, in a study to examine effect of treatment of active inflammation with 5-ASA drugs on cytokeratin expression in the colon. Decision pending and no funding currently received. The decision for the laboratory consumables is that Warner Chilcott have not provided and will not be providing any funding for this project.</p> <p>Planned participation in "IBD Ahead" meeting, 17.6.10, sponsored by Abbott Pharmaceuticals discussing questions relating to management of inflammatory bowel disease. My participation in the IBD ahead of the</p>	None

GDG meeting	Declaration of Interests	Action taken
	meeting on 17th June 2010 was to contribute to discussion of the literature relating to clinical questions in Crohn's disease. I will receive no honorarium for this, though travel expenses are paid. My contribution was to the sections on the use of glucocorticosteroid treatment and I was present for the discussion of the other questions.	
3rd GDG meeting 26th Oct 10	I attended the American Gastroenterology Association meeting in June 2010, sponsored by Abbott Pharmaceuticals, manufacturers of the anti-TNF agent, adalimumab. This covered hotel and travel costs (economy flights) and registration at the meeting. Not considering biological treatments in this GDG.	None
	The department have been considering use of an IBD database - and have met with companies for two systems. One would be funded by Ferring and the other by Warner Chilcott - both manufacturers of 5 amino-salicylic acids. We have not made a decision about whether we will use one of these - or neither. The Ferring database is in use in the other hospital in the Trust, but I do not work there, except on-call, do not use the system and had no role in its procurement or implementation. I am involved in the running of the Yorkshire and Humber IBD network; the logistic arrangements for which (so, far hire of room only) are made by a representative for Warner Chilcott. I have taken no fee for this since that declared on my original form in June.	None
9th GDG meeting 14th Jun 11	Chairing Yorkshire and Humber IBD Network meeting sponsored by Abbott, Biohit, MSD and Warner Chilcott in June 16, 2011. No personal payment received. 8 CPD points approved by the Royal College of Physicians - on the basis of it being an independent meeting. Approval was given to another person on behalf of the Yorkshire and Humber IBD network, not to any company. Attending pre-meeting dinner (15 June) to welcome international speakers. Will not receive sponsorship for this. Will be attending United European Gastroenterology Week and flights and accommodation paid by Abbott Pharmaceuticals.	None
11th GDG meeting 7th Sept 11	United European Gastroenterology Week funded by Abbott Pharmaceuticals (manufacturers of the anti-TNF adalimumab). They will fund accommodation and flights to the meeting in Stockholm, which is the main European gastroenterology meeting.	None
14th GDG meeting 14th Dec 11	<p>Travel bursary awarded by Shire Innovation Fund (5-ASA [Mezavant]) to a specialist registrar to attend United European Gastroenterology Week (UEGW), 2011 and to present work on azathioprine metabolism. Application made independently by the Specialist Registrar.</p> <p>The money will be paid into the NHS Trust account for which Alan Lobo is a named signatory, but will be ring fenced solely for the purposes of travel of the named specialist registrar to UEGW 2011.</p>	None
17th GDG meeting 3rd Jul 12	Non-personal non-specific pecuniary interest relating to the Yorkshire and Humber IBD network of which I am co-chair/mentor – previously declared. (May 2012) by Warner Chilcott into the “Treasurers account Yorkshire and Humber IBD network” for setting up and running of the Yorkshire and IBD network. I have no personal access to this account.	None

GDG meeting	Declaration of Interests	Action taken
	One of my colleagues has run two meetings for General Practitioners in Sheffield. Sponsorship was received to run the meeting from a number of companies (Warner-Chilcott, Ferring, Shire, Pfizer, Astra Zeneca, Dr Schar, Abbott, Dr Falk). There was no input to the content of the meeting from anyone other than the speakers and chairs. I spoke at both of these, and co-chaired one. There was no payment to me.	None
Andy Player		
1st GDG meeting (8th Sept 10) until submission of guidance (3rd Jul 12)	None made.	None required
Jayne Kranat		
1st GDG meeting 8th Sept 10) until submission of guidance (3rd Jul 12)	None made.	None required
Jenny Lee		
1st GDG meeting (8th Sept 10) until submission of guidance (3rd Jul 12)	None made.	None required
John Mayberry		
	Declared at interview that he had written a number of patient information booklets over the last 20 years.	
3rd GDG meeting 26th Oct 10	Specific non-personal pecuniary interest in that his colleague was awarded a grant for research into adherence in IBD by Shire Pharmaceuticals and grant for 2 year research into training of nurses and their attitudes to adherence from Warner Chilcott.	No action
4th GDG meeting 8th Dec 10	Non-personal pecuniary interest declared: At the end of last week my research colleague received notice that she would be awarded a fee by Warner Chilcott (manufacturer of Asacol) for her work on traditional diets and their use as a treatment in ulcerative colitis. This does not include any work on drug therapy or enteral nutrition. The grant is awarded to her and administered by University Hospitals of Leicester NHS Trust.	No action
5th GDG meeting 11th Jan 11	Non-personal pecuniary interest declared - a colleague who works with me and another colleague has received a grant from Shire Pharmaceuticals to conduct Participatory Workshops amongst patients of South Asian origin and patients who are deaf on what are the barriers they experience and what would be their solutions to treatment for	No action

GDG meeting	Declaration of Interests	Action taken
	ulcerative colitis. This covers consultations, investigations, treatment and surveillance. It follows on from her work (yet to be published other than as abstracts) which shows that patients from such communities receive poorer care. It is an aspect of the Patient Benefit Program I mentioned at my interview - but this money is clearly from a pharmaceutical company. It is a benefit in kind. The control of the money will lie with UHL NHS Trust and a colleague.	
6th GDG meeting 2nd Mar 11	Warner Chilcott is proposing to pay a fee for my information booklets (the first versions were produced 20 years ago). There are 4 different titles. I propose that the money should go into the departmental research funds and that the money is paid to University Hospitals of Leicester NHS Trust. At GDG meeting, JM updated that Warner Chilcott were no longer interested in distributing the Crohn's disease patient information booklet.	Following the withdrawal of the declaration, no action was required.
7th GDG meeting 5th Apr 11	Non-personal pecuniary interest declared: a fee was paid to UHC NHS trust by Warner Chilcott for further versions of booklet for patients with IBD. One of the booklets is about Crohn's disease.	No action required
11th GDG meeting 7th Sept 11	Personal pecuniary non-specific declaration of interest from Arla, who make lactose free products (of no specific relevance to Crohn's disease).	No action required
14th GDG meeting 14th Dec 11	Personal, non-pecuniary interest declared - appointed to the Herbal Medicines Board (part of MHRA) from 1 December 2012 for four years.	No action required
John Nicholls		
3rd GDG meeting 26th Oct 10	Specific, non-personal pecuniary interest in that he administers a Scottish IBD database funded by Shire Pharmaceuticals (5-ASA, [mezavant]).	Present during discussions about 5-ASAs but did not take part in decisions about recommendations. The original decision reviewed in light of: *Mezavant – although it is a 5-ASA it was not looked at in the guideline as the drug is not used for CD – used for ulcerative colitis *Shire make no other drugs used in CD or considered in the guideline

Declarations of interest
Declarations of interest

GDG meeting	Declaration of Interests	Action taken
11th GDG meeting 7th Sept 11	Personal pecuniary interest declared as adviser to Shire (5-ASA, [mezavant]). Research into diverticular disease.	No action
16th GDG meeting 22nd Feb 12	Submitted a grant application to Pfizer and Abbott (adalimumab) but that this has not been agreed.	No action
17th GDG meeting 3rd Jul 12	Non personal specific pecuniary grant (account at the St Mark's Research Foundation (John Nicholls named account) from Abbott (biologic [adalimumab] and nutritional products) for research into mortality in Crohn's disease by the Scottish NHS Information Service Division.	Withdrew from the meeting when stakeholder comments and recommendations relating to adalimumab and enteral nutrition were discussed
Mark Follows		
1st GDG meeting (8th Sept 10) until he withdrew from the GDG (Mar 2011).	None made.	None required
Mary Brennan		
3rd GDG meeting 26th Oct 10	Attended a Ferring (Pentasa [5-ASA])-sponsored IBD nurse study day.	No action
5th GDG meeting 11th Jan 11	Fee from National Association for Crohn's and Colitis for accommodation and registration at the BSPGHAN winter meeting 26-28 January, 2011.	No action
11th GDG meeting 7th Sept 11	Study co-ordinator for constipation study funded by Movartis. Non-personal non-specific pecuniary interest. Awaiting approval. Non-personal pecuniary interest declared - payment to departmental education fund for presentation on childhood constipation (November 2011). Personal pecuniary interest in that expenses paid by representative.	No action
12th GDG meeting 11th Oct 11	Non-pecuniary interest declared for reviewing the NACC "IBD concerns for Young People" information sheet.	No action
14th GDG meeting 14th Dec 11	Fee from National Association for Crohn's and Colitis for accommodation and registration at the BSPGHAN winter meeting 26-28 January, 2011.	No action

Declarations of interest
Declarations of interest

GDG meeting	Declaration of Interests	Action taken
15th GDG meeting 25th Jan 12	Personal pecuniary interest: Dr Falk (make Budenofalk [budesonide] and Salofalk [mesalazine] paid expenses for an overnight stay and dinner to attend a team meeting.	Declare and participate
16th GDG meeting 22nd Feb 12	Personal pecuniary interest declared: Warner Chilcott (ex Proctor & Gamble) makes Asacol. Paid to develop the IBD Nurse Leadership Toolkit, accessible via the IBDigest Website. Complete around April 2010.	Withdrew for relevant recommendations at GDG meeting 16 when recommendations were agreed and signed off
Sarah Cripps		
10th GDG meeting 6th Jul 11	Personal pecuniary interest declared as speaking on epidemiology and pathology of IBD at UKCPA hepatology masterclass 29062011. UKCPA confirmed payment for travel and fees is not directly from industry sponsors (Ferring, MSD, Abbott, Warner Chilcott) of the event.	No action
15th GDG meeting 25th Jan 12	Personal pecuniary but non-specific interest declared from Medicys (market research company) for completing a questionnaire investigating use of biological treatments within gastroenterology.	Declare and participate
Trevor Jones		
1st GDG meeting (8th Sept 10 until submission of guidance (3rd Jul 12)	None made.	None required
Helen Ludlow		
2nd GDG meeting 29th Sept 10 (declarations made at recruitment 19 Sept)	Personal pecuniary interest declared: Warner Chilcott (ex Procter & Gamble) makes Asacol (hardly ever used in Crohn's anyway). Paid to develop the IBD Nurse Leadership Toolkit, accessible via the IBDigest Website, not drug related in anyway, and was done through Oyster, an educational company. The work I did was completed around April 2010.	No action
	Dr Falk - the work was not drug- specific related, but information leaflets for patients and GPs about avoiding unnecessary glucocorticosteroid use and when to seek urgent help. This work is ongoing but I could pull out of it. Dr Falk - along with a few other BD CNS's we have been aiming to put together a document for GPs on the primary care management of patients with Crohn's and avoiding the inappropriate use of glucocorticosteroid, when to refer etc. This has yet to be completed and published.	No Action
3rd GDG meeting 26th Oct 10	Non-personal pecuniary interest by Ferring (Pentasa [mesalazine]) to Department's funds in February 2011 for participation in a debate about the effect of IBD nurses on SPR training. Also declared a personal pecuniary interest in that she was sponsored by	The chair decided that she could be present during discussions about 5-ASAs but could

GDG meeting	Declaration of Interests	Action taken
	Falk and Abbott Pharmaceuticals to attend two IBD nurse study days (travel and expenses only).	not take part in decisions about recommendations
5th GDG meeting 11th Jan 11	Non-personal pecuniary interest for Advisory board for Abbott Pharmaceuticals (produce anti-TNF), to update nurse and patient information packs. Money to Hospital Trust.	No action
10th GDG meeting 6th Jul 11	<p>Non pecuniary interest declared: evening sponsored by Abbot generally about IBD and when to start medications at all levels, led by 3 Gastroenterology Consultants (no one speaking from Abbot). Non pecuniary interest declared: Feb 2012 Shire (mezavant) sponsoring attendance at the ECCO Conference in Barcelona (travel, accommodation and conference fees).</p> <p>Non-pecuniary interest declared: Friday 1 July, meeting by Falk (Budesonide) about IBD (not drug-specific). Free to attend and open to all Gastroenterology teams from this part of the UK.</p>	No action
12th GDG meeting 11th Oct 11	Personal pecuniary interest declared - Shire sponsorship of expenses for attendance at Feb 2012 ECCO conference.	No action
16th GDG meeting 22 Feb 12		Withdrew for recommendations pertaining to budesonide and 5-ASA treatment at GDG meeting 16 when recommendations were agreed and signed off
Alex Ford		
1st GDG meeting 8th Sept 10	Personal pecuniary interest paid by The American College of Gastroenterology for being involved in the technical side (not the actual writing) of the American College of Gastroenterology's monograph on the management of IBD, which will be published early next year. I am not an acknowledged author of the monograph itself, but performed the meta-analyses that will underpin the recommendations made in the monograph (literature searches, assessment of eligibility, data extraction, writing the papers). As a result I have already published data on the efficacy of 5-ASAs in post-operative Crohn's disease (in press with the American Journal of Gastroenterology), and will be publishing data on the efficacy of 5-ASAs in inducing remission in Crohn's and preventing relapse.	Chair deemed none necessary
9th GDG meeting 14th Jun 11	Personal pecuniary non-specific declaration of interest: Speakers fees from GE medical. GE medical don't make a drug, they market a diagnostic test called the SeHCAT scan for bile acid malabsorption. Personal pecuniary Digestive Diseases Week 2011 Conference expenses (flights and hotel) from Shire.	Chair deemed none necessary

GDG meeting	Declaration of Interests	Action taken
11th GDG meeting 7th Sept 11	Personal pecuniary specific speakers fee from Shire (make Mezavant - not licensed for or used in Crohn's disease) in August for talking about management of chronic idiopathic constipation.	No COI because: *although it is a 5-ASA, Mezavant was not looked at in the guideline as the drug is not used for CD – used for ulcerative colitis *Shire make no other drugs used in Crohn's disease or considered in the guideline
16th GDG meeting 22 Feb 12	Personal non-specific pecuniary declaration: from MSD (make infliximab) for speaker fees: Meeting the challenges of being a new consultant. (November 2011). The fee was paid to me, but I immediately transferred this into my research account. MSD sponsored flights and accommodation to attend ECCO 2012.	No action